MiNK Therapeutics annual depreciation and amortization
2020
2021
2022
2023
2024
2025
MiNK Therapeutics Depreciation & Amortization Growth & History (INKT)
MiNK Therapeutics's depreciation and amortization was $181,745 for fiscal 2025.
View full MiNK Therapeutics company overviewMiNK Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $181,745 | −$33,692 | −15.64% |
| 2024 | 2024-12-31 | $215,437 | $10,820 | +5.29% |
| 2023 | 2023-12-31 | $204,617 | $82,868 | +68.06% |
| 2022 | 2022-12-31 | $121,749 | $43,789 | +56.17% |
| 2021 | 2021-12-31 | $77,960 | $22,900 | +41.59% |
| 2020 | 2020-12-31 | $55,060 | — | — |
MiNK Therapeutics quarterly depreciation and amortization
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $36,064 | −$12,699 | −26.04% |
| Q1 2026 | 2026-03-31 | $36,066 | −$14,699 | −28.95% |
| Q4 2025 | 2025-12-31 | $38,563 | — | — |
| Q3 2025 | 2025-09-30 | $43,654 | −$18,983 | −30.31% |
| Q2 2025 | 2025-06-30 | $48,763 | $3,663 | +8.12% |
| Q1 2025 | 2025-03-31 | $50,765 | −$3,066 | −5.70% |
| Q3 2024 | 2024-09-30 | $62,637 | $9,184 | +17.18% |
| Q2 2024 | 2024-06-30 | $45,100 | −$6,806 | −13.11% |
| Q1 2024 | 2024-03-31 | $53,831 | $8,145 | +17.83% |
| Q3 2023 | 2023-09-30 | $53,453 | $25,023 | +88.02% |
| Q2 2023 | 2023-06-30 | $51,906 | $23,597 | +83.36% |
| Q1 2023 | 2023-03-31 | $45,686 | $18,609 | +68.73% |
| Q3 2022 | 2022-09-30 | $28,430 | $8,145 | +40.15% |
| Q2 2022 | 2022-06-30 | $28,309 | $10,662 | +60.42% |
| Q1 2022 | 2022-03-31 | $27,077 | $10,883 | +67.20% |
| Q3 2021 | 2021-09-30 | $20,285 | — | — |
| Q2 2021 | 2021-06-30 | $17,647 | — | — |
| Q1 2021 | 2021-03-31 | $16,194 | — | — |
MiNK Therapeutics depreciation and amortization trends
Over the last five fiscal years, MiNK Therapeutics's depreciation and amortization increased from $55,060 to $181,745, a change of $126,685. The latest reported quarter, Q2 2026, shows $36,064.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MiNK Therapeutics source filings ↗